title: Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression.
abstract: Fibrate derivatives are commonly used to treat hyperlipidaemia; however, the mechanism of the antilipidaemic action of these drugs is still unknown. The effect of clofibrate (fibrate derivative) administration for 14 days on lipogenesis and on malic enzyme (EC 1.1.1.40) and fatty acid synthase (EC 2.3.1.85) gene expression in brown and white adipose tissues and in the liver was examined in rats. The rate of brown adipose tissue lipogenesis in the clofibrate-treated animals was significantly lower than that of the control rats. The rate of liver and white adipose tissue lipogenesis was not affected significantly by clofibrate. In brown adipose tissue, the drug treatment resulted in a depression of fatty acid synthase and malic enzyme mRNA levels. The fatty acid synthase mRNA level did not change significantly in the liver, whereas the malic enzyme mRNA level increased approximately 6-fold in this organ after clofibrate treatment. The malic enzyme mRNA level in white adipose tissue increased about 2-fold, while the fatty acid synthase mRNA level was unchanged after clofibrate feeding. The results presented in this paper provide further evidence that the hypolipidaemia caused by treatment of rats with clofibrate cannot be related to the inhibition of fatty acid synthesis in the liver and white adipose tissue. These data also indicate that clofibrate exhibits tissue specificity.
authors.affiliation: Department of Biochemistry, Medical University of Gdansk, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Karbowska
authors.forename: Z
authors.initials: Z
authors.lastname: Kochan
authors.forename: L
authors.initials: L
authors.lastname: Zelewski
authors.forename: J
authors.initials: J
authors.lastname: Swierczynski
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D000818:Animals; D015152:Blotting, Northern; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology*; D064429:Fatty Acid Synthases / Q000235:genetics / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008055:Lipids / Q000096:biosynthesis* / Q000235:genetics; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D008291:Malate Dehydrogenase / Q000235:genetics / Q000378:metabolism; D008297:Male; D009928:Organ Specificity / Q000235:genetics; D012313:RNA / Q000302:isolation & purification; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids; D012333:RNA, Messenger; D014280:Triglycerides; D012313:RNA; D002784:Cholesterol; D008291:Malate Dehydrogenase; C031917:malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+); D064429:Fatty Acid Synthases; D002994:Clofibrate